Evidence map›Paper›PMID 40576820›Full record

ArticleClinical and experimental medicine2025

Integrated analysis of CD30 detection methodologies and synergistic drug combinations for optimizing brentuximab vedotin therapy in lymphoma.

Mingyu Ye, Tao Wang, Zhiqiang Song, Xuefei Liu, Ping Liu, Ling Zhang, Gusheng Tang, Miaoxia He, Na Liu, Jianmin Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mingyu Ye *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Tao Wang *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Zhiqiang Song *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Xuefei LiuDepartment of Pathology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Ping LiuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Ling ZhangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Gusheng TangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Miaoxia HeDepartment of Pathology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Na LiuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. liuna2015@sibs.ac.cn.
Jianmin YangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate, has shown significant efficacy in CD30-positive lymphoma. However, the relationships between CD30 expression levels and BV efficacy remains unclear. In this study, we first evaluated the reliability of CD30 detection by immunohistochemistry (IHC) and found that flow cytometry (FCM) offers higher sensitivity and accuracy in assessing CD30 expression. Therefore, FCM may serve as a more effective method for evaluating CD30 levels. Furthermore, we confirmed a positive correlation between CD30 expression levels and BV efficacy. However, even when BV was applied to tumor cells with 100% CD30 expression, its anti-tumor activity did not reach complete eradication, highlighting the need for synergistic combination therapies. To address this, we conducted high-throughput screening (HTS) and identified auranofin and napabucasin as synergistic agents that enhance the efficacy of BV. These findings not only highlight the advantages of FCM for CD30 detection, but also provide valuable insights into combination strategies to optimize the therapeutic potential of BV.

Indexed as

Antineoplastic Agents, ImmunologicalBrentuximab VedotinImmunoconjugatesKi-1 AntigenLymphomaAntineoplastic Combined Chemotherapy ProtocolsAuranofinCell Line, TumorDrug SynergismFlow CytometryHigh-Throughput Screening AssaysHumansImmunohistochemistryAntineoplastic Agents, ImmunologicalAuranofinBrentuximab VedotinImmunoconjugatesKi-1 Antigen

Identifiers

PMID40576820
PMCPMC12204884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.